Table 1.
Characterization of 27 carbapenem-resistant A. baumannii (CRAB) clinical isolates used in this study.
| Bacterial Strains | MIC of AS101 | Susceptibility to Antimicrobial Agents 1 | Gene Detection of Carbapenemase | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CL | GM | DOX | CAZ | TIC | LEV | MEM | |||
| TSP-AB-1 | 8 | S | R | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-2 | 2 | S | R | S | R | R | R | R | blaIMP-1, blaOXA-69 |
| TSP-AB-3 | 2 | S | R | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-4 | 8 | S | R | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-5 | 2 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-6 | 8 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-7 | 2 | S | S | S | R | R | I | R | blaOXA-24, blaOXA-69 |
| TSP-AB-8 | 8 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-9 | 2 | S | R | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-10 | 1 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-11 | 1 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-12 | 16 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-13 | 32 | S | R | R | R | R | R | R | blaVIM-2, blaOXA-69 |
| TSP-AB-14 | 0.5 | S | R | R | R | R | R | R | - |
| TSP-AB-15 | 4 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-16 | 4 | S | S | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-17 | 2 | S | R | R | R | R | R | R | - |
| TSP-AB-18 | 0.5 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-19 | 1 | S | R | R | R | R | R | R | - |
| TSP-AB-20 | 1 | S | R | R | R | R | R | R | - |
| TSP-AB-21 | 2 | S | I | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-22 | 2 | S | R | R | R | R | R | R | blaOXA-24, blaOXA-69 |
| TSP-AB-23 | 1 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-24 | 8 | S | I | R | R | R | R | R | bla OXA-69 |
| TSP-AB-25 | 1 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-26 | 2 | S | R | R | R | R | R | R | bla OXA-69 |
| TSP-AB-27 | 8 | S | S | R | R | R | R | R | bla OXA-69 |
| Resistant rate | N/A 2 | 0% | 81.5% | 92.6% | 100% | 100% | 96.3% | 100% | N/A |
| 0/27 | 22/27 | 25/27 | 27/27 | 27/27 | 26/27 | 27/27 | |||
1 Abbreviations: CL, Colistin; GM, Gentamicin; DOX, Doxycycline; CAZ, Ceftazidime; TIC, Ticarcillin; LEV, Levofloxacin; MEM, Meropenem. Interpretation of antimicrobial susceptibility was according to criteria recommended by CLSI: S, susceptible; I, intermediate; R, resistant. 2 N/A, not applied.